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Abstract
Increasing evidence indicates that decreased functional
beta-cell mass is the hallmark of both Type 1 and Type
2 diabetes. This underlies the absolute or relative insu-
lin insufficiency in both conditions. In this For Debate,
we consider the possible mechanisms responsible for
beta-cell death and impaired function and their relative
contribution to insulin insufficiency in diabetes. Beta-
cell apoptosis and impaired proliferation consequent to
hyperglycaemia is one pathway that could be operating
in all forms of diabetes. Autoimmunity and other
routes to beta-cell death are also considered. Recogni-
tion of decreased functional beta-cell mass and its
overlapping multifactorial aetiology in diabetic states,
leads us to propose a unifying classification of diabe-
tes. [Diabetologia (2004) 47:581–589]
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degree and that Type 2 diabetes is a complex patho-
physiologic spectrum encompassing situations reflect-
ing the combination of beta-cell failure or demise and
insulin resistance to varying degrees. More recently, the
debate has been complicated by equally heated discus-
sion on the cause of impaired insulin secretion: is this
due to reduced beta-cell mass or to an intrinsic defect in
the secretory machinery of the beta-cells or both? Now
that the significant reduction in beta-cell mass observed
many years ago [5, 6] has been clearly established in
Type 2 diabetes [7, 8, 9], studies must focus on whether
such a reduction alone can account for impaired insulin
secretion and on the molecular mechanism responsible
for the decreased beta-cell mass.
Insufficient insulin secretion in Type 2 diabetes
The defect in insulin secretion in Type 2 diabetes is the
consequence of two confounding components: insulin
deficiency and disturbed kinetics of secretion combined
with impaired glucose stimulus-secretion coupling.
Insulin deficiency. It cannot be stressed enough that
insulin deficiency in Type 2 diabetes is relative to the
Type 1 diabetes is recognised as a condition of absolute
insulin deficiency due to destruction of beta cells. To
the extent that this aetiology is not in dispute, it will not
be a major focus of this For Debate. By contrast, Type
2 diabetes was for many years attributed solely to insu-
lin resistance. Although altered insulin secretion in pa-
tients with Type 2 diabetes had already been demon-
strated in the 1960’s [1, 2, 3], it was not until the 1980’s
that the debate on the true aetiology of the disease be-
came heated. Thus, once the reality of impaired beta-
cell function in Type 2 diabetes was acknowledged
even by the most fervent champions of insulin resis-
tance [4], this debate focused in the first instance on the
relative importance of these two components and their
putative respective causality. There is now general
agreement that all hypotheses were correct to a certain
prevailing hyperglycaemia and reflects the analytical
methods used. The simple measurement of circulating
concentrations of immunoreactive insulin at least at
early stages of the disease, shows hyperinsulinaemia.
Clearly, however, this level of immunoreactive insulin
is insufficient to control the prevailing hypergly-
caemia: hence “insulin deficiency”. Most convention-
al assays detect both proinsulin and insulin indiffer-
ently. Yet, it has been known for some time that Type
2 diabetes is characterised by an increased ratio of
proinsulin:insulin [10, 11] and that the biological ac-
tivity of proinsulin is approximately 10% that of fully-
processed insulin. Thus, in order to assess the hypo-
glycaemic potential of circulating insulin, one should
in reality consider only the true insulin component
rather than total immunoreactivity (reflecting all im-
munoreactive species including proinsulin and con-
version intermediates). When this is done, the insulin
deficiency becomes more evident. In addition, most
measurements are done on a single fasting blood sam-
ple, yet it is under these conditions that the demand
for insulin is at its lowest. Only after stimulation does
the magnitude of the insulin deficiency become fully
manifest. Leaving aside the specific defect in glucose
stimulation, even a potent stimulus such as arginine
elicits a markedly diminished insulin response in pa-
tients with Type 2 diabetes [12]. Thus, we have shown
that after an i.v. arginine challenge, patients with Type
2 diabetes and with a high fasting concentration of im-
munoreactive insulin (163% of the control subjects)
only released 62% as much immunoreactive insulin as
the control subjects [11].
Beta-cell secretory defect. Insulin secretion from
subjects with Type 2 diabetes is characterised by a
relatively selective loss of glucose stimulation mani-
fested by the lack of first phase of secretion and de-
creased second phase. Sensitivity to non-metabolis-
able stimuli such as arginine remains normal al-
though the magnitude of the response may be attenu-
ated. Baseline insulin secretion is normally pulsatile,
with a periodicity of 5 to 10 min. Such pulsatility of
insulin secretion, believed to be important for normal
glucose homeostasis, is also perturbed in Type 2 dia-
betes as are the ultradian oscillations of insulin se-
cretion [13, 14]. This could in addition, at least in
part, account for some insulin resistance [15, 16, 17].
These defects in secretion, and particularly the lack
of response towards glucose, act in concert with the
insulin deficiency along with a disproportionate
amount of proinsulin. Together, they compromise
severely the ability of residual beta cells to provide
sufficient insulin to achieve euglycaemia in the face
of insulin resistance. When evaluated during an
OGTT, these secretory defects can be observed
shortly after glucose ingestion.
Decreased beta-cell mass in Type 2 diabetes
It was suggested many years ago that beta-cell mass is
reduced in Type 2 diabetes ([18] and see [19] for a
more recent review). This decrease in beta-cell mass
has been confirmed by a series of convincing studies
in which beta-cell mass was quantified morphometri-
cally in a large series of pancreata from patients with
Type 2 diabetes and appropriately matched control
subjects [7, 8, 9]. Thus, and most importantly, obese
patients with Type 2 diabetes have decreased beta-cell
mass compared to obese individuals without diabetes.
This suggests that in patients with Type 2 diabetes
there is a loss of beta cells and/or impaired augmenta-
tion of beta-cell mass consequent to increased de-
mand. By contrast, the beta-cell mass in non-obese
control subjects was not significantly different to that
of obese patients with Type 2 diabetes. This could ex-
plain the discrepancies in earlier studies. By defini-
tion, any change in beta-cell mass must reflect an al-
tered balance between the rate of production (whether
by neogenesis or replication of beta cells) and disap-
pearance (cell death by necrosis or apoptosis). It is
difficult to distinguish between the two mechanisms in
human tissue sections mainly because dead cells are
removed rapidly from the islet by macrophages and
neighbouring cells, making it hard to quantify cell
death. Although cell proliferation can be quantified in
tissue sections using markers such as Ki-67, this only
provides a single snapshot in time which probably
does not reflect accurately the complex dynamic of
the process. Nevertheless, one study in humans does
indicate that increased apoptosis is of greater impor-
tance in the reduced beta-cell mass of Type 2 diabetes
than impaired neogenesis and/or proliferation [8]. It is
important to note that these studies in humans cannot
be prospective in nature, given that they were done at
autopsy. Most specifically, the beta-cell mass in these
individuals before onset of the disease is not known.
Thus individuals susceptible to diabetes possibly have
limited beta-cell mass early in life, perhaps even at
birth, due to genetic or environmental factors. If such
were the case, the decrease in beta-cell mass seen in
patients with Type 2 diabetes would not necessarily be
the sole consequence of the disease itself.
Mechanism of beta-cell death in Type 2 diabetes
Major mechanisms proposed to lead to beta-cell death
in Type 2 diabetes and discussed here include: in-
creased circulating cell nutrients, ER-stress, signalling
factors from the adipocyte, and iatrogenic mecha-
nisms. This For Debate is obviously not all-inclusive.
Without any prejudice towards the other mechanisms
and their relative importance, as well as the valuable
contributions of the respective authors, we focus pri-
marily on the pro-apoptotic effect of hyperglycaemia
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and dyslipidaemia on beta cells and possible molecu-
lar pathways (Fig. 1). Significant omissions include
the possible pro-apoptotic roles of IAPP [20, 21, 22,
23] and inflammatory factors [24, 25, 26].
From hyperglycaemia to beta-cell death. It is impor-
tant to stress that glucose affects survival of human
and rodent islets differently. This has led to a certain
amount of confusion in the field. In brief, graded in-
creases in glucose from 5.6 to 11.2 mmol/l and above
induce apoptosis of human beta cells in vitro in a
dose-related fashion [27, 28]. By contrast, studies on
rat islets have shown that increasing glucose from a
physiological concentration of 5.6 to 11.2 mmol/l de-
creases apoptosis [29]. A further increase above
11.2 mmol/l has been shown to be either pro- or anti-
apoptotic depending on the study [29, 30]. However,
islets from psammomys obesus, a gerbil, behave like
human islets [31]. This small animal and humans both
develop nutrient-dependent forms of diabetes, possi-
bly reflecting the importance of glucose-mediated
beta-cell loss in these two settings. In this context, it is
important to consider the possible detrimental effect
on beta-cell turnover of transient post-prandial gly-
caemic excursions early in the development of overt
diabetes. This could perhaps underlie the decrease in
beta-cell mass documented in patients with impaired
fasting glucose, the earliest manifest stage of diabetes
[8]. The situation is confounded by the fact that (in ro-
dents) glucose can also stimulate proliferation [32]
and neogenesis [33, 34] of beta cells: the relative im-
pact on proliferation and apoptosis will thus dictate
the outcome of decreased or increased beta-cell mass
[19]. Furthermore, the mitogenic effects of glucose, at
least in vitro, seem to be limited in time in human is-
lets [28] but are long-lasting using rat islets. The mass
of beta cells at any given time is thus the consequence
of a complex algorithm reflecting glucose concentra-
tion, time, proliferation and apoptosis.
Given that glucose does induce apoptosis in beta
cells what might be the mechanism? One clue may lie
in the relative specificity of this toxicity towards the
beta cell, but not other islet or most non-islet cell
types. This cell is by design exquisitely sensitive to
small changes in ambient glucose. When these chang-
es are of short duration and in the physiological range
as after a meal, they lead to insulin secretion. Howev-
er, when of longer duration and more pronounced in
magnitude, perhaps they are translated by the beta-cell
glucose-sensing pathways into pro-apoptotic signals.
One such signal might be increased ER-stress [35, 36,
37]. The increased demand on beta cells in terms of
insulin output leads to increased secretion as well as
increased proinsulin biosynthesis to replenish beta-
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Fig. 1. Proposed model for the interplay between “aggressors”
of the beta cell in the pathogenesis of diabetes. Factors possi-
bly affecting beta-cell survival should be considered represen-
tative of the given pathway; the list is not intended to be com-
prehensive. Signalling pathways within the beta-cell leading to
apoptosis are not included. Increased concentrations of glucose
and lipids (NEFA, LDL, VLDL) are believed to have deleteri-
ous effects on beta cells. Lipids might affect the viability of
beta cells directly or via obesity. Similarly, cytokines secreted
by adipocytes (i.e. TNFα, IL-6 and leptin) could act directly
on beta cells or activate the innate immune system. In turn, in-
nate immunity could favour an acquired immune response in
genetically predisposed individuals. Additional factors precipi-
tating beta-cell demise in diabetic patients include viruses and
drugs. The aetiology of the particular diabetic condition and in
turn the precise role and respective importance of each pro-
apoptotic pathway will vary from one patient to the next
cell insulin stores [38]. The increase in proinsulin bio-
synthesis in turn causes an increased flux of protein
through the RER. Flux through the RER of the beta
cell is quite high compared with other cell types even
under physiologic conditions and any further increase
is expected to tilt the balance in favour of ER-stress-
induced apoptosis. Chronic hyperglycaemia could also
lead to long-term increases in cytosolic Ca++ [as op-
posed to the normal short-term increases arising from
glucose-induced closure of ATP-dependent potassium
channels (KATP)] that could in turn be pro-apoptotic
[39]. High glucose also leads to the generation of re-
active oxygen species (ROS) [40, 41], believed to be
particularly toxic to the beta cell. We have shown, us-
ing human islets, that high glucose in vitro activates
an additional and unexpected apoptotic pathway in-
volving beta-cell production of IL-1β, activation of
NFκB and Fas signalling [42]. This was confirmed in
beta cells in sections of pancreata from patients with
Type 2 diabetes [42]. This last pathway may turn out
to be a unifying mechanism for beta-cell death in dis-
ease. The situation is complicated by the fact that as
mentioned above, glucose (at least in vitro) has a dual
effect on human beta-cell turnover, promoting prolif-
eration in the short-term and apoptosis in the longer
term [28]. We have suggested a common factor, FLIP
providing a switching mechanism between these two
opposing effects [43].
From dyslipidaemia to beta-cell death. Diabetes is as-
sociated with dyslipidaemia characterised by in-
creased circulating concentrations of NEFA and
changes in lipoprotein profiles. Both have been shown
to be pro-apoptotic in the beta cell [44, 45]. Intrigu-
ingly, saturated fatty acids such as palmitate are high-
ly toxic to the beta cell whereas the mono-unsaturated
fatty acids such as oleate are protective against both
palmitate and glucose-induced apoptosis [46]. A simi-
lar balance between pro- and anti-apoptotic effects is
found for lipoprotein action on beta-cell survival.
VLDL and LDL are thus pro-apoptotic whereas HDL
protects beta cells against these pro-apoptotic effects
[45]. Fatty acid cytotoxicity is mediated by the cera-
mide-mitochondrial apoptotic pathway [47] whereas
pro-apoptotic lipoproteins seem to act via c-Jun N-ter-
minal kinase (JNK) [45]. Regardless of the impor-
tance of these pro-apoptotic pathways in some situa-
tions, dyslipidaemia is not common to all patients
with Type 2 diabetes. Furthermore, toxicity of lipids
towards beta cells may be influenced by or possibly
dependent upon the prevailing glycaemia [48, 49].
The interplay and relative importance of beta-cell
death caused by glucose or fatty acids/lipoproteins
could thus vary from one patient to another. Addition-
ally, other pathways may come into play. We have
thus discovered that leptin, the protein hormone re-
leased by adipocytes, in addition to its established ef-
fect on insulin secretion [50, 51], induces apoptosis in
human beta cells (Maedler et al; submitted for publi-
cation). This contradicts previous studies on rodent is-
lets showing that leptin protects against NEFA-in-
duced apoptosis [52]. Whether this reflects the use of
rodent versus human islets or a truly selective protec-
tive effect remains to be investigated.
Is there a common pathway linking reduced 
beta-cell mass and impaired beta-cell function?
Clearly, loss of enough beta cells will lead to de-
creased insulin output from the pancreas. The interest-
ing question is whether this is an “all-or-nothing” phe-
nomenon, with a more or less direct relationship be-
tween beta-cell mass and function, or whether partial
loss of beta-cell mass leads directly or indirectly to
impaired secretion from the remaining cells. Before
speculating on this, let us examine the known facts. In
humans, before impaired glucose tolerance becomes
apparent (the earliest manifestation of incipient diabe-
tes) there may have been loss of as much as ~50% of
beta-cell mass [8]. Surprisingly, as overt diabetes de-
velops, further loss might be quite limited, amounting
to no more than an additional 10% or so [8]. This cer-
tainly points to a secondary or parallel impairment of
beta-cell function. Again in humans, hemi-pancreatec-
tomy led to impaired beta-cell function [53] whereas
in rats, partial pancreatectomy results in impaired in-
sulin secretion resembling that encountered in Type 2
diabetes despite extensive regeneration of the remnant
and only very modest increase in glycaemia at the
time of study [54]. Taken together, one must conclude
that decreased beta-cell mass can lead to impaired
function but the mechanism is not apparent nor is it
necessarily the sole answer.
Two mechanisms possibly account for such im-
paired beta-cell function consequent to decreased
beta-cell mass: (i.) increased insulin demand on resid-
ual beta cells per se leads to changes in function
(whether by ER-stress or other mechanisms), (ii.) hy-
perglycaemia consequent to decreased beta-cell mass
drives the impairment in beta-cell function. Distin-
guishing between the two is complicated by the fact
that decreasing beta-cell mass experimentally more
often than not leads to a more or less prolonged period
of hyperglycaemia [55, 56]. Moreover, in many in-
stances there is a compensatory regeneration of beta
cells. Newly formed beta cells might not be as well-
differentiated as older, fully mature residents in the
pancreas. Regardless, there is ample evidence from in
vitro studies on islets (e.g. [57, 58]) as well as in vivo
by glucose infusion (e.g. [59]), that high glucose for
extended periods of time leads to impaired beta-cell
secretory behaviour. Although we agree with Gordon
Weir et al. that “excessive glucose stimulation of a re-
duced beta-cell mass leads to functional abnormalities
of the beta cell” [60], this is surely just one factor.
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Consequently we acknowledge that the initial events
leading to the progressive increase in glycaemia seen
in diabetes remain elusive. For example, a genetic
component combined with excessive food intake may
lead to clinically undetectable hyperglycaemic excur-
sions that could have an effect at an early stage on
beta-cell mass and/or function. Furthermore, glucose
is just one factor influencing beta-cell mass. Finally,
we stress the importance of the amplitude and dura-
tion of hyperglycaemia. It is thus known that shorter
periods of increased glucose in humans in fact in-
crease glucose sensitivity of insulin secretion [12, 62].
Whereas Type 2 diabetes in humans progresses
over time, impaired beta-cell function appears to be
reversible to a certain degree at all stages. Thus, if an
individual with Type 2 diabetes, even with severe hy-
perglycaemia, is rendered euglycaemic by either phar-
macological means or changes in life-style, beta-cell
function, and in particular glucose-responsiveness, is
restored [63, 64]. This is particularly true at early
stages of the disease where the limiting threshold for
reversibility of decreased beta-cell mass has perhaps
not been passed. Rendering an individual with Type 2
diabetes euglycaemic interrupts the vicious cycle link-
ing decreased beta-cell function with hyperglycaemia.
This might not only restore insulin secretory patterns
but also allow for some restoration of beta-cell mass.
Although there are many reasons for believing that
this may occur in humans as in animal models of re-
duced beta-cell mass, it has never been documented
directly and it will be difficult to do so as long as beta-
cell mass cannot be measured non-invasively.
Unravelling the pathways leading to beta-cell death
and impaired function may provide the basis for inno-
vative therapy of Type 2 diabetes. This is particularly
true when one considers the reversibility of impaired
beta-cell function and possibly beta-cell mass dis-
cussed above. One example might prove to be long-
acting analogues of GLP-1 (or inhibitors of the en-
zyme DPP IV that degrades GLP-1) that will be in
clinical use to enhance insulin-secretion but could
have additional beneficial effects on beta-cell mass by
stimulating proliferation and inhibiting apoptosis [65,
66]. Other examples for innovative therapy are KATP
channel openers. Treatment with diazoxide not only of
patients with Type 1 but also with Type 2 diabetes,
partially restores insulin secretion [67, 68, 69]. While
this beneficial effect may be due to inducing beta-cell
“rest”, it could also reflect in part the anti-apoptotic
effect of such drugs [29]. We believe that IL-1β secre-
tion by the beta cell might be a common pathway link-
ing hyperglycaemia to both impaired beta-cell func-
tion and beta-cell apoptosis. Blocking IL-1β sig-
nalling could thus be useful in treating Type 2 diabe-
tes. Use of the natural soluble IL-1 receptor antago-
nist, IL-1Ra, might serve this purpose and we are cur-
rently investigating the effect of this protein in a clini-
cal trial in Type 2 diabetes.
Decreased beta-cell mass as a common 
denominator of Type 1 and Type 2 diabetes: 
clinical consequences and implications 
for the classification of diabetes
Current classification of diabetes distinguishes be-
tween Type 1 and Type 2 [70]. Type 1 diabetes is de-
fined by beta-cell destruction and subdivided into im-
mune-mediated and idiopathic. For Type 2 diabetes,
no mention is made of possible beta-cell loss. Emerg-
ing theories from basic scientists and diabetologists
alike, are tending towards a unifying hypothesis of di-
abetes. While it is probable that genetic predisposition
is an important feature in all forms of diabetes, ad-
vances in the field do not yet allow for useful classifi-
cation on this basis and indeed do not exclude the
broad spectrum of diabetic conditions we propose. So
what is the evidence for blurring and overlapping dia-
betic conditions? Immunological phenomena (e.g.
anti-islet cell antibodies) typically associated with
Type 1 diabetes are encountered in 10 to 20% of so-
called Type 2 diabetic patients, which led to a separate
classification of these patients in a subtype named
“LADA” (latent autoimmune diabetes of adults). We
now have paediatricians studying islet cell autoimmu-
nity in elderly diabetic patients [71]. Consider also the
intriguing theory that obesity could underlie the ob-
served increase in Type 1 diabetes [72], a causal cor-
relation which has been recently confirmed in two in-
dependent studies [73, 74]. Meanwhile, clinical re-
search has shown that changes in inflammatory cy-
tokines are not limited to classic autoimmune-type di-
abetes but are increased in Type 2 diabetes [75, 76]
and could indeed be useful as markers of risk for de-
veloping the disease [77]. That being said, this is also
the case in obesity, in turn suggesting an intrinsic
beta-cell defect of some kind that renders individuals
susceptible to progressing from obesity to diabetes.
Clearly the time-course and extent of loss of beta
cells, in association with varying degrees of insulin re-
sistance, will affect the clinical manifestations of the
disease. Autoimmune destruction of the majority of
beta cells in young individuals will lead to a rapid on-
set of the disease and if treatment is delayed, ketoaci-
dosis will occur. This is rarely seen in adults with
Type 1 diabetes, therefore referred to as suffering
from LADA. The situation is, however, complicated
by anecdotal reports from paediatricians describing
the dynamics of the regression of beta-cell function in
young Type 2 diabetic patients as much more rapid
than in adult counterparts. If this observation holds
true, there will be obvious therapeutic implications.
Observations from the basic scientist are equally il-
luminating. Apoptosis in the presence of cytokines in-
cluding IL-1β may lead to an autoimmune response
[78]. Moreover, both beta-cell apoptosis [8] and an in-
crease of locally produced IL-1β [42] are observed in
Type 2 diabetes. Furthermore, signalling networks pre-
viously believed to be limited to islets of patients with
Type 1 diabetes are detectable in islets from patients
with Type 2 diabetes, e.g. Fas-FasL, IL-1β [28, 42, 43].
As mentioned above, apoptosis itself may induce an au-
toimmune response. Interestingly, apoptosis of beta
cells precedes the emergence of insulitis in the NOD
mouse [79] and lymphocyte infiltration is also observed
consequent to apoptosis in islets of immune-competent
Pdx1+/− mice [80]. Therefore beta-cell apoptosis,
whether genetically programmed, or induced by a virus,
IAPP, glucose or NEFA could prove to be a very early
event. Depending on its magnitude and duration, sec-
ondary phenomena including insulitis may appear with
different timing and severity, thus escaping notice.
There has to our knowledge been no systematic attempt
to detect insulitis in the pancreas of early-onset Type 2
diabetes. That being said, we do not ignore some mor-
phological findings that appear to be specific to Type 2
diabetes, most specifically islet amyloid deposits, but
they are not found in all cases of Type 2 diabetes just as
insulitis has not been detected in all Type 1 cases exam-
ined. In both cases, we also recognise the importance of
the timing of the events leading to such manifest mor-
phological features; depending on this timing with re-
spect to the age of the subject at autopsy and duration
of the disease, these “morphological markers” may or
may not be apparent. Certainly, it is not our intention to
refute the existence of auto-immune diabetes. However,
and as acknowledged by the Expert Committee on Di-
agnosis and Classification of Diabetes [70], beta-cell
destruction in Type 1 diabetes can, in addition, arise by
other mechanisms. Furthermore, as mentioned, immu-
nological marker and inflammatory mediators are also
detected in Type 2 diabetic patients. While we certainly
do believe that autoimmune diabetes exists, the frontier
between this form of diabetes and others is, to our
mind, blurred.
Increasing evidence would now suggest that beta-
cell death underlies most forms of diabetes. While the
aetiology of beta-cell death may vary from one condi-
tion to the next, we reason that it will inevitably result
in a state of insulin deficiency and impaired beta-cell
function. We are not alone. According to his “Acceler-
ator hypothesis”, Wilkin states: “Clinically, there is
little other than tempo to distinguish two types of dia-
betes” [81]. Therefore, we and others (e.g. [75, 81])
believe that the classification of diabetes should be re-
visited. The clinical definition of diabetes can contin-
ue to be that proposed by the American Diabetes As-
sociation and now generally accepted [70, 82]. In all
instances, we now propose that individuals with these
clinical features suffer from one of many conditions of
relative or absolute insulin deficiency, that we propose
calling simply “diabetes mellitus”. The only sub-
sidiary question is whether the patient has, in addition
to insulin deficiency, insulin resistance. While an ob-
jective and ready index of insulin resistance does not
exist in the absence of reliable and easily measurable
surrogate markers, it may be sufficient in most cases
to note whether the patient presents with obesity (and
metabolic syndrome) and/or has a family history sug-
gestive of insulin resistance. We propose the follow-
ing subtypes in our classification: diabetes mellitus
with or without insulin resistance, with or without au-
toantibodies.
So what is new? We already have just two major
subtypes of diabetes: Types 1 and 2. Are we simply
changing names? No. The fundamental difference is
that our classification provides intrinsic guidelines for
therapy since insulin resistance can be easily detected
and indeed modulated. If present, insulin sensitivity
should be targeted by lifestyle intervention, shown to
be so effective in recent American, Chinese and Euro-
pean studies [83, 84, 85]. The earlier such intervention
in the progression of the disease (i.e. patients with im-
paired glucose tolerance rather than overt diabetes)
the better. This can be supplemented by insulin-sensi-
tising agents. If these strategies fail or are insufficient,
the next step could be to replace what is missing, i.e.
insulin. We do recognise that insulin resistance is not
peculiar to Type 2 diabetes. Indeed, patients with Type
1 diabetes can present with insulin resistance and/or
obesity and this may be induced or exacerbated by in-
tensive insulin therapy. The sub-classification “with or
without autoantibodies”, alas, has no impact on thera-
py today. Nevertheless, we include this as an incentive
for further research leading towards targeted therapy
and perhaps ultimately a means to prevent or slow
down autoimmune destruction of beta cells.
What are the pitfalls? We do not underestimate the
possibly negative effects of extensive use of insulin
therapy: the menace of hypoglycaemia may be more
of a concern than with other therapy. Moreover, it is
generally accepted that patients, particularly the elder-
ly, may be reluctant to treat themselves by injection.
Insulin therapy does require greater support from
health professionals and this could pose a problem. Fi-
nally, as we all recognise, exogenous insulin is not the
perfect replacement for secretion from the beta cell.
Many aspects of physiological insulin delivery are
missing and this probably affects its efficacy. Certain-
ly, we do not wish to promote irresponsible use of
medication (whether insulin or other) when behav-
ioural changes (moderate exercise and improved diet)
can be efficacious. On the other hand, it is mandatory
that patients with absolute insulin deficiency, as seen
typically in younger lean individuals, receive insulin
from the very beginning of the disease as currently
practised by most diabetologists.
Given the rationale behind this approach to diabe-
tes, namely that decreased beta-cell mass underlies all
common forms of the disease, particular attention
should be paid to the possible beta-cell toxic side-ef-
fects of any supplementary or alternative medication.
For example, it is suggested from in vitro studies that
sulphonylureas could have such effects both on rat
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[29] and human islets [86]. Whether these studies turn
out to be of clinical relevance remains to be seen but
they are in line with an important recent prospective
study comparing insulin and sulphonylurea treatment
of Type 2 diabetes. This study shows that treatment
with insulin preserved beta-cell function more effec-
tively than glibenclamide [87]. It remains to be estab-
lished whether it is the beneficial effects per se of in-
sulin or possible beta-cell toxicity of glibenclamide
that account for this observation. While a deterioration
of insulin secretion was seen in patients treated with
sulphonylurea in the UKPDS, those treated with insu-
lin were not evaluated in this regard [60]. This should
not, however, detract from use of what have been
shown to be effective drugs particularly in the elderly
in whom any possible acceleration in the decrease of
beta-cell mass could be of less clinical relevance. At
the other extreme, prolonged use of any drug that
could negatively affect beta-cell mass in young pa-
tients is clearly not indicated. It is too early to know
whether the new generation of oral secretagogues
such as the glinides will negatively or positively affect
beta-cell turnover with prolonged use.
Summary and conclusion
We present evidence in support of the hypothesis that
diabetes is a spectrum of clinical conditions all of
which arise from relative or absolute insulin deficien-
cy that is caused by decreased functional beta-cell
mass. Hyperglycaemia is suggested to be a major, but
not the only, driving force for beta-cell death. This
does not, of course, exclude the existence of autoim-
mune diabetes and neither does it diminish its impor-
tance. The same goes for the genetic predisposition to
diabetes. Current classification of diabetes is inade-
quate. We propose a new classification focused on de-
creased functional beta-cell mass and consequent in-
sulin deficiency with two subtypes based on the pres-
ence or absence of insulin resistance and/or autoim-
munity.
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